Badrinath Konety Named UMP CEO & Vice Dean of Clinical Affairs

October 19, 2018
Published by
Published by: 
Naomi McDonald, Director of Communications and Marketing

Dr. Badrinath Konety, MD, MBA, Head, Department of Urology has been named as the new CEO of University of Minnesota Physicians (UMP) and Vice Dean of Clinical Affairs for the Medical School.

Dr. Konety is a nationally and internationally recognized expert on prostate and bladder cancer and proven academic and clinical leader. He currently serves as the Dougherty Family Chair in Uro-Oncology, Director of the Institute for Prostate and Urologic Cancers, and the Medical School’s Associate Dean for Strategy and Innovation. He has also served on the UMP Board of Directors and as the Chair of the Board's Finance Committee. He co-led the Funds Flow workgroup during our negotiations with Fairview this summer and played a key role in our ability to co-create a new future.

As CEO, Dr. Konety will serve on the Executive Leadership Team of M Health Fairview and will oversee, with his dyad partners, service lines and shared clinical services throughout the health system. In addition, he will lead our work to further the UMP/Medical School operational alignment which will ensure the strength of the group practice and our capability to fulfill our land-grant mission to serve our state.
 
As Vice Dean of Clinical Affairs for the Medical School, Dr. Konety will build innovative clinical partnerships, develop and steward the Master Clinician track, play a key role in faculty recruitments, serve on the Dean’s leadership team, and lead in strategic planning efforts for the clinical mission.

In an email announcement, Dean Tolar said Dr. Konety “brings a successful academic track record, spirit of entrepreneurship, and a deep commitment to our practice and this Medical School.”

An interim chair for the Department of Urology will be named while a national search is conducted for a new permanent leader. Dr. Konety will assume his new role on December 1, 2018.

Share this post

You may also like:

Dr. Morse comes from the University of Colorado, Denver, where she was the Medical Director of Research at Craig Hospital and Clinical Associate Professor of Physical Medicine and Rehabilitation.

GT MedTech’s innovative GammaTile Therapy is shown to slow brain tumor progression, designed to improve patient and caregiver quality of life.

Perlingeiro’s lab, over several years, pioneered the development of muscle stem/progenitor cells from pluripotent stem cells in vitro.